Drug Profile
Research programme: T cell receptor cancer therapeutics - Kite Pharma/Leiden University Medical Center
Latest Information Update: 28 Feb 2020
Price :
$50
*
At a glance
- Originator Kite Pharma; Leiden University Medical Center
- Class Antineoplastics; Immunotherapies
- Mechanism of Action Cell replacements; T-cell receptor gene modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Feb 2020 No recent reports of development identified for research development in Solid-tumours in Netherlands (Parenteral)
- 03 Oct 2017 Kite Pharma has been acquired by Gilead Sciences
- 13 May 2016 9195659- relevant info already updated